JACKSON — Mississippi will receive $532,675 part of a $35 million settlement with a Pfizer Inc. subsidiary over the marketing of an organ-transplant drug.
Mississippi and 41 other states are involved in the settlement with Pfizer, the parent company of Wyeth Pharmaceuticals Inc. The deal resolves allegations Wyeth misrepresented the uses of the drug Rapamune.
A statement from Mississippi Attorney General Jim Hood says “state consumer protection laws were violated by misrepresentation of the uses and benefits of Rapamune.”
Rapamune was approved to help prevent the rejection of kidney transplants. The states alleged the company promoted it to doctors for uses following other organ transplants.
New York-based Pfizer says in a statement the alleged activity occurred before it acquired Wyeth. Pfizer didn’t admit wrongdoing or liability as part of the settlement.
BEFORE YOU GO…
… we’d like to ask for your support. More people are reading the Mississippi Business Journal than ever before, but advertising revenues for all conventional media are falling fast. Unlike many, we do not use a pay wall, because we want to continue providing Mississippi’s most comprehensive business news each and every day. But that takes time, money and hard work. We do it because it is important to us … and equally important to you, if you value the flow of trustworthy news and information which have always kept America strong and free for more than 200 years.
If those who read our content will help fund it, we can continue to bring you the very best in news and information. Please consider joining us as a valued member, or if you prefer, make a one-time contribution.Click for more info